Literature DB >> 10049087

Doxorubicin-induced cardiomyopathy.

S M Swain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10049087

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase.

Authors:  Michael J Mihm; Fushun Yu; David M Weinstein; Peter J Reiser; John Anthony Bauer
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.

Authors:  Thiago Ferreira de Souza; Thiago Quinaglia A C Silva; Felipe Osorio Costa; Ravi Shah; Tomas G Neilan; Lício Velloso; Wilson Nadruz; Fabricio Brenelli; Andrei Carvalho Sposito; Jose Roberto Matos-Souza; Fernando Cendes; Otávio Rizzi Coelho; Michael Jerosch-Herold; Otavio Rizzi Coelho-Filho
Journal:  JACC Cardiovasc Imaging       Date:  2018-08

3.  Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment.

Authors:  Anne Blaes; Daniel Duprez; Todd Defor; Ryan Shanley; Heather Beckwith; Tufia Haddad; David Potter; Douglas Yee; Kinjal Sanghavi; Pamala Jacobson
Journal:  Springerplus       Date:  2015-01-23

4.  A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis.

Authors:  Ting Chen; Hong-Mei Shen; Zhi-Yong Deng; Zuo-Zhang Yang; Rui-Lian Zhao; Li Wang; Zhi-Ping Feng; Chao Liu; Wen-Hui Li; Zhi-Jie Liu
Journal:  Mol Med Rep       Date:  2017-03-01       Impact factor: 2.952

5.  Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS/EPC pathway.

Authors:  Wen-Pin Huang; Wei-Hsian Yin; Jia-Shiong Chen; Po-Hsun Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.